Santarus Reports First Quarter 2012 Financial ResultsMarketWatch (press release)CYCLOSET(bromocriptine mesylate) tablets new prescriptions increased 67% and total prescriptions were up 172% in the first quarter of 2012 compared with the first quarter of 2011.
Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR ... - Reuters
Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR .
Santarus Announces Presentation of UCERIS Phase III Extended Use Data at ... - MarketWatch (press release)
Santarus Announces Presentation of UCERIS Phase III Extended Use Data at .
Santarus to Present at Bank of America Merrill Lynch 2012 Health Care Conference - MarketWatch (press release)
Santarus to Present at Bank of America Merrill Lynch 2012 Health Care ConferenceMarketWatch (press release)The company's current commercial efforts are focused on GLUMETZA(R) (metformin hydrochloride extended release tablets) and CYCLOSET(R) (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in .